Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 168

1.

S-100A1 is a reliable marker in distinguishing nephrogenic adenoma from prostatic adenocarcinoma.

Cossu-Rocca P, Contini M, Brunelli M, Festa A, Pili F, Gobbo S, Eccher A, Mura A, Massarelli G, Martignoni G.

Am J Surg Pathol. 2009 Jul;33(7):1031-6. doi: 10.1097/PAS.0b013e31819c6ff9.

PMID:
19384190
2.

Expression of alpha-methylacyl-coenzyme A racemase in nephrogenic adenoma.

Gupta A, Wang HL, Policarpio-Nicolas ML, Tretiakova MS, Papavero V, Pins MR, Jiang Z, Humphrey PA, Cheng L, Yang XJ.

Am J Surg Pathol. 2004 Sep;28(9):1224-9.

PMID:
15316323
4.

Nephrogenic adenoma: immunohistochemical evaluation for its etiology and differentiation from prostatic adenocarcinoma.

Xiao GQ, Burstein DE, Miller LK, Unger PD.

Arch Pathol Lab Med. 2006 Jun;130(6):805-10.

PMID:
16740031
5.

PAX2: a reliable marker for nephrogenic adenoma.

Tong GX, Melamed J, Mansukhani M, Memeo L, Hernandez O, Deng FM, Chiriboga L, Waisman J.

Mod Pathol. 2006 Mar;19(3):356-63.

6.

Revisiting the immunophenotype of nephrogenic adenoma.

Fromont G, Barcat L, Gaudin J, Irani J.

Am J Surg Pathol. 2009 Nov;33(11):1654-8. doi: 10.1097/PAS.0b013e3181b40061.

PMID:
19730362
7.

Immunohistochemistry in diagnostic surgical pathology of the prostate.

Hameed O, Humphrey PA.

Semin Diagn Pathol. 2005 Feb;22(1):88-104. Review.

PMID:
16512601
9.
10.

Altered expression of alpha-methylacyl-coenzyme A racemase in prostatic adenocarcinoma following hormone therapy.

Suzue K, Montag AG, Tretiakova M, Yang XJ, Sahoo S.

Am J Clin Pathol. 2005 Apr;123(4):553-61.

PMID:
15743746
11.

Discovery and clinical application of a novel prostate cancer marker: alpha-methylacyl CoA racemase (P504S).

Jiang Z, Woda BA, Wu CL, Yang XJ.

Am J Clin Pathol. 2004 Aug;122(2):275-89. Review.

PMID:
15323145
12.
13.

Alpha-methylacyl-CoA racemase (P504S)/34betaE12/p63 triple cocktail stain in prostatic adenocarcinoma after hormonal therapy.

Sung MT, Jiang Z, Montironi R, MacLennan GT, Mazzucchelli R, Cheng L.

Hum Pathol. 2007 Feb;38(2):332-41. Epub 2006 Nov 28.

PMID:
17134736
14.

Alpha-methylacyl-CoA racemase: a variably sensitive immunohistochemical marker for the diagnosis of small prostate cancer foci on needle biopsy.

Magi-Galluzzi C, Luo J, Isaacs WB, Hicks JL, de Marzo AM, Epstein JI.

Am J Surg Pathol. 2003 Aug;27(8):1128-33.

PMID:
12883245
15.

Alpha-Methylacyl-CoA racemase: a novel tumor marker over-expressed in several human cancers and their precursor lesions.

Zhou M, Chinnaiyan AM, Kleer CG, Lucas PC, Rubin MA.

Am J Surg Pathol. 2002 Jul;26(7):926-31.

PMID:
12131161
16.

Alpha-methylacyl-CoA racemase: a multi-institutional study of a new prostate cancer marker.

Jiang Z, Wu CL, Woda BA, Iczkowski KA, Chu PG, Tretiakova MS, Young RH, Weiss LM, Blute RD Jr, Brendler CB, Krausz T, Xu JC, Rock KL, Amin MB, Yang XJ.

Histopathology. 2004 Sep;45(3):218-25.

PMID:
15330799
17.

Alpha-methylacyl-CoA racemase as a marker in the differential diagnosis of metanephric adenoma.

Olgac S, Hutchinson B, Tickoo SK, Reuter VE.

Mod Pathol. 2006 Feb;19(2):218-24.

18.

Nephrogenic adenoma of the urinary tract: a review.

Alexiev BA, LeVea CM.

Int J Surg Pathol. 2012 Apr;20(2):123-31. doi: 10.1177/1066896912439095. Epub 2012 Mar 13. Review.

PMID:
22415059
19.

Nephrogenic adenoma of the prostatic urethra: a mimicker of prostate adenocarcinoma.

Allan CH, Epstein JI.

Am J Surg Pathol. 2001 Jun;25(6):802-8.

PMID:
11395559
20.

Prospective evaluation of AMACR (P504S) and basal cell markers in the assessment of routine prostate needle biopsy specimens.

Browne TJ, Hirsch MS, Brodsky G, Welch WR, Loda MF, Rubin MA.

Hum Pathol. 2004 Dec;35(12):1462-8.

PMID:
15619204

Supplemental Content

Support Center